Qiagen (NYSE:QGEN) Releases Q1 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.540- for the period, compared to the consensus earnings per share estimate of 0.600. The company issued revenue guidance of $487.8 million-, compared to the consensus revenue estimate of $511.8 million. Qiagen also updated its FY 2026 guidance to 2.500- EPS.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of recent research reports. Barclays set a $58.00 price target on shares of Qiagen and gave the company an “overweight” rating in a research note on Friday. Stifel Nicolaus set a $50.00 price target on Qiagen and gave the stock a “hold” rating in a report on Friday. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research report on Friday. Citigroup decreased their price objective on Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft downgraded Qiagen from a “buy” rating to a “hold” rating and raised their target price for the stock from $52.00 to $54.00 in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $54.68.

Qiagen Price Performance

NYSE:QGEN traded up $0.08 during trading hours on Friday, hitting $51.31. 1,511,822 shares of the company’s stock traded hands, compared to its average volume of 3,130,321. The firm has a market cap of $10.84 billion, a P/E ratio of 25.45, a P/E/G ratio of 2.48 and a beta of 0.67. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81. The business’s fifty day simple moving average is $49.63 and its two-hundred day simple moving average is $49.67. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.82% and a net margin of 20.33%.The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, research analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Institutional investors and hedge funds have recently made changes to their positions in the stock. Boston Partners bought a new stake in shares of Qiagen during the 3rd quarter worth $179,450,000. Dimensional Fund Advisors LP bought a new stake in Qiagen during the third quarter worth about $58,079,000. Caisse de depot et placement du Quebec purchased a new position in shares of Qiagen in the 3rd quarter worth about $27,082,000. Invesco Ltd. boosted its holdings in shares of Qiagen by 123.7% in the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock worth $48,350,000 after purchasing an additional 556,387 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its position in shares of Qiagen by 162.0% during the 3rd quarter. Balyasny Asset Management L.P. now owns 854,386 shares of the company’s stock valued at $38,174,000 after purchasing an additional 528,245 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.